Despite the efficacy of bupropion for smoking cessation, smokers exhibit variability in
treatment outcome. The CYP2B6 gene has been implicated in bupropion kinetics and …

Many smokers attempt to quit smoking but few are successful in the long term. The
heritability of nicotine addiction and smoking relapse have been documented, and research …

Metabolic capacities for debrisoquin, sparteine, mephenytoin, nifedipine, and midazolam,
which are substrates of polymorphic CYP2D6, CYP2C19, and CYP3A, have been reported …

CYP2A6 is the main enzyme that catalyzes nicotine into cotinine. Interindividual differences
in nicotine metabolism result at least partially from polymorphic variation of CYP2A6 gene. In …

Cytochrome P450 1B1 (CYP1B1), a phase I enzyme, is involved in the activation of a broad
spectrum of procarcinogens. An association of the Cyp1B1 L432V polymorphism with …

Background and Objective The in vivo implication of various cytochrome P450 (CYP)
isoforms and of P‐glycoprotein on methadone kinetics is unclear. We aimed to thoroughly …

Background There is growing evidence that genetic factors also contribute to drug addiction.
The human cytochrome P450 has shown special interest because of pharmacokinetic …

Background Genetic variability may influence methadone metabolism, dose requirements,
and risk of relapse. Objectives To determine whether the CYP2B6* 6 or ABCB1 (rs1045642) …

Nicotine is the primary addictive compound in tobacco smoke. In this review we summarize
nicotine dependence and the genetics of smoking in brief before focusing on cytochrome …

What is known and objective Pharmacogenomics holds promise in smoking cessation
because of its potential to shed light on the complexity of drug metabolism and improve …